Antígens menors d'histocompatibilitat en el trasplantament al·logènic de progenitors hematopoètics. Modulació de la resposta en funció del genotip CTLA-4

Text Complet
Minor histocompatibility antigens (mHAgs) are peptides derived from polymorphic intracellular proteins that can be recognized in an allogeneic setting by the donor T-lymphocytes leading to the appearance of graft-versus-host disease (GvHD); however, the correlation between mHAgs and this complication is a matter of debate. Polymorphisms on the CTLA-4 gene have been previously associated with autoimmune diseases, predisposition to leukemic relapse, and with GvHD or relapse after allogeneic transplant. There are no studies exploring if these polymorphisms may modulate the ability of the immune system to develop responses in the presence of a specific antigen; and nor studies regarding the effect of CTLA-4 polymorphisms on alloimmune recognition when the allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed with exhaustive T cell depletion through CD34-positive selection (allo- HSCT-CD34), where the immune response will depend on the newly generated T cells from the infused stem. Our hypothesis was that mHAgs disparities have an impact in clinical outcome after allo-HSCT from sibling donor; that the CTLA-4 genotype of the donor may modulate the ability of the allogeneic T lymphocytes to respond in front of mHAg mismatches, even when the graft is T cell depleted ​
​L'accés als continguts d'aquesta tesi queda condicionat a l'acceptació de les condicions d'ús establertes per la següent llicència Creative Commons: